<DOC>
	<DOCNO>NCT01885598</DOCNO>
	<brief_summary>The primary objective study examine safety profile Eliquis Korean nonvalvular atrial fibrillation patient .</brief_summary>
	<brief_title>Eliquis Regulatory Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients â‰¥19 year age Adult patient diagnose nonvalvular atrial fibrillation initiate Eliquis anticoagulation therapy risk reduction stroke systemic embolism Patients evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect study Receiving Eliquis treatment indication approve Korea Contraindicated use Eliquis describe Korean label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>